SCHEMBL342965

SCHEMBL342965

CCCCCCCCCC(=O)N[C@@H](CCCCN)C(=O)O

nearest known ligand 0.85

Predicted protein targets (top 8)

geneUniProtsupporting neighboursconfidence
SLC6A5 Q9Y345 2/20 0.85
NOD1 Q9Y239 13/20 0.75
ITGB3 P05106 1/20 0.58
ITGA2B P08514 1/20 0.58
FOLH1 Q04609 1/20 0.55
FAAH O00519 1/20 0.55
DNM1 Q05193 1/20 0.54
EPHX2 P34913 1/20 0.54

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1245563 1.00 SLC6A5 (0.85) SLC6A5NOD1ITGB3ITGA2BFOLH1
SCHEMBL343693 1.00 SLC6A5 (0.85) SLC6A5NOD1ITGB3ITGA2BFOLH1
SCHEMBL9716739 1.00 SLC6A5 (0.85) SLC6A5NOD1ITGB3ITGA2BFOLH1
SCHEMBL9716727 1.00 SLC6A5 (0.85) SLC6A5NOD1ITGB3ITGA2BFOLH1
SCHEMBL5946236 1.00 SLC6A5 (0.85) SLC6A5NOD1ITGB3ITGA2BFOLH1
SCHEMBL2166697 1.00 SLC6A5 (0.85) SLC6A5NOD1ITGB3ITGA2BFOLH1
SCHEMBL1487710 1.00 SLC6A5 (0.85) SLC6A5NOD1ITGB3ITGA2BFOLH1
SCHEMBL1982744 1.00 SLC6A5 (0.85) SLC6A5NOD1ITGB3ITGA2BFOLH1
SCHEMBL15474 1.00 SLC6A5 (0.85) SLC6A5NOD1ITGB3ITGA2BFOLH1
SCHEMBL4020128 1.00 SLC6A5 (0.85) SLC6A5NOD1ITGB3ITGA2BFOLH1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 42 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-10195127-B2 Cosmetic composition AJINOMOTO CO., INC. (JP) 2019-02-05 US claimed
US-20250082560-A1 PARTICLES AND USE THEREOF MATSUMOTO YUSHI-SEIYAKU CO., LTD. (JP) 2025-03-13 US disclosed
EP-4442736-A1 PARTICLES AND USE THEREOF Matsumoto Yushi-Seiyaku Co., Ltd. (JP) 2024-10-09 EP disclosed
WO-2023139987-A1 PARTICLES AND USE THEREOF 松本油脂製薬株式会社 2023-07-27 WO disclosed
CN-112251473-B Preparation of N by using microreactorεMethod for producing-lysine-based surfactant 南京先进生物材料与过程装备研究院有限公司 2022-07-22 CN disclosed
CN-114423445-A Treatment of neurological diseases using complement inhibitors RA制药公司 2022-04-29 CN disclosed
CN-113966224-A Treatment of inflammatory diseases with complement inhibitors RA制药公司 2022-01-21 CN disclosed
CN-112251473-A Preparation of N by using microreactorεMethod for producing-lysine-based surfactant 南京先进生物材料与过程装备研究院有限公司 2021-01-22 CN disclosed
US-10786437-B2 Composition for cosmetics and cosmetics comprising same AJINOMOTO CO., INC (JP) 2020-09-29 US disclosed
US-10736826-B2 Cream-like composition AJINOMOTO CO., INC. (JP) 2020-08-11 US disclosed
US-20110281792-A1 BINDING-SITE MODIFIED LECTINS AND USES THEREOF SMARTCELLS, INC. 2011-11-17 US disclosed
US-20110281939-A1 POLYNUCLEOTIDE APTAMER-BASED CROSS-LINKED MATERIALS AND USES THEREOF SMARTCELLS, INC. 2011-11-17 US disclosed
US-20110281791-A1 CRYSTALLINE INSULIN-CONJUGATES SMARTCELLS, INC. 2011-11-17 US disclosed
US-20110275560-A1 SYNTHETIC CONJUGATES AND USES THEREOF SMARTCELLS, INC. 2011-11-10 US disclosed
US-6869930-B1 Acylated insulin NOVO NORDISK A/S (DK) 2005-03-22 US disclosed
EP-0473700-A1 AN ENZYME-CATALYZED PROCESS FOR PREPARING N-ACYL AMINO ACIDS AND N-ACYL AMINO ACID AMIDES NOVO NORDISK A/S (DK) 1992-03-11 EP disclosed
EP-0178911-B1 COMPOSITION CONTAINING A PENEM OR CARBAPENEM ANTIBIOTIC SANKYO COMPANY LIMITED (JP) 1992-01-22 EP disclosed
WO-1990014429-A1 AN ENZYME-CATALYZED PROCESS FOR PREPARING N-ACYL AMINO ACIDS AND N-ACYL AMINO ACID AMIDES NOVO NORDISK A/S (DK) 1990-11-29 WO disclosed
US-4757066-A Reduces renal toxicity SANKYO COMPANY LIMITED (JP) 1988-07-12 US disclosed
EP-0178911-A2 Composition containing a penem or carbapenem antibiotic SANKYO COMPANY LIMITED (JP) 1986-04-23 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20110275560-A1 SYNTHETIC CONJUGATES AND USES THEREOF SLC2A4, SLC2A8, CD44 SLC6A5 807/4885NOD1 2390/4885ITGB3 385/4885
US-20110281791-A1 CRYSTALLINE INSULIN-CONJUGATES IAPP, INSR, GPR119 SLC6A5 1203/4885NOD1 2258/4885ITGB3 2565/4885
US-10195127-B2 Cosmetic composition CUTA, H1-0, AADAT SLC6A5 2031/4885NOD1 4769/4885ITGB3 2883/4885
US-20110281792-A1 BINDING-SITE MODIFIED LECTINS AND USES THEREOF SIGLEC7, SIGLEC9, LGALS3BP SLC6A5 1804/4885NOD1 870/4885ITGB3 508/4885
US-20110281939-A1 POLYNUCLEOTIDE APTAMER-BASED CROSS-LINKED MATERIALS AND USES THEREOF PNKP, ADAR, NCL SLC6A5 2550/4885NOD1 1364/4885ITGB3 692/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.